Doctor Reported Outcomes: Real-World Data from a Tertiary Eye Cancer Center
January 30, 2024: Published in the Indian Journal of Ophthalmology, Dr. Finger along with other ECF affiliated professionals, Drs. Puneet Jain, Ankit Tomar, Abhilasha Masheshwari, and Gaurav Garg released this abstract to provide real-world data to the public to spread patient and doctor awareness.
Doctor Reported Outcomes: Patients Want To Know!
The Eye Cancer Foundation supported research to create a program that allows for near real time “Doctor Reported Outcomes” to be published online. Specifically, the results of all patients returning to The New York Eye Cancer Center have their results anonymously average in with other patients that share a diagnosis. The first diseases were choroidal melanoma, iris and ciliary body melanoma, and ocular surface squamous carcinoma. That means, right now, Dr. Finger’s near real-time results can be viewed on the home page of the web site www.eyecancer.com. Here, Dr. Finger’s simple, understandable statistics reveal the average outcomes achieved for his patients.
The Eye Cancer Foundation invites other centers to share this free software. Then patients can compare the results from multiple centers. Published in the literature, results obtained from December 2017 to January 2020, were published by Dr. Finger’s fellow Abhilasha Maheshwari, MD and co-workers. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926100/)
But the DRO continues to provide data added every week. Patient results were anonymized, entered in an online portal, and sent to a unique software program. Published outcomes include the number of patients, average vision, local tumor control, eye salvage, systemic metastases, and length of follow-up at The New York Eye Cancer Center.
Abstract
Purpose: To provide real-world data on the world-wide-web for patient and doctor awareness.
Methods: From December 2017 to January 2020, consecutive patients with choroidal melanoma (CM), iris ciliary body melanoma (ICM), and ocular surface squamous carcinoma (OSSC) had specific outcomes recorded at each return visit. Each result was anonymized, entered in an online portal, and sent to a unique software program where it was used to create real-world data of number of patients, mean vision, local tumor control, eye salvage, systemic metastases, and length of follow-up for our eye cancer center.
See the results and conclusion to this abstract on PubMed here: https://pubmed.ncbi.nlm.nih.gov/33323598/
Doctor Reported Outcomes: Patients Want To Know!
The Eye Cancer Foundation supported research to create a program that allows for near real time “Doctor Reported Outcomes” to be published online. Specifically, the results of all patients returning to The New York Eye Cancer Center have their results anonymously average in with other patients that share a diagnosis. The first diseases were choroidal melanoma, iris and ciliary body melanoma, and ocular surface squamous carcinoma. That means, right now, Dr. Finger’s near real-time results can be viewed on the home page of the web site www.eyecancer.com. Here, Dr. Finger’s simple, understandable statistics reveal the average outcomes achieved for his patients.
The Eye Cancer Foundation invites other centers to share this free software. Then patients can compare the results from multiple centers. Published in the literature, results obtained from December 2017 to January 2020, were published by Dr. Finger’s fellow Abhilasha Maheshwari, MD and co-workers. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926100/)
But the DRO continues to provide data added every week. Patient results were anonymized, entered in an online portal, and sent to a unique software program. Published outcomes include the number of patients, average vision, local tumor control, eye salvage, systemic metastases, and length of follow-up at The New York Eye Cancer Center.
Abstract
Purpose: To provide real-world data on the world-wide-web for patient and doctor awareness.
Methods: From December 2017 to January 2020, consecutive patients with choroidal melanoma (CM), iris ciliary body melanoma (ICM), and ocular surface squamous carcinoma (OSSC) had specific outcomes recorded at each return visit. Each result was anonymized, entered in an online portal, and sent to a unique software program where it was used to create real-world data of number of patients, mean vision, local tumor control, eye salvage, systemic metastases, and length of follow-up for our eye cancer center.
See the results and conclusion to this abstract on PubMed here: https://pubmed.ncbi.nlm.nih.gov/33323598/